VCA Augments Doxorubicin Efficacy in Triple-Negative Breast Cancer: Evidence for Multi-Pathway Synergism
BIOCELL · 2025 · 49 (12) · 2377-2397
DOI: 10.32604/biocell.2025.072360 ↗Kurz gefasst
Fachartikel in der Zeitschrift BIOCELL, 2025. Verfasst von Chang-Eui Hong und 1 weiteren Autor:innen. Die Arbeit wurde bisher 3-mal zitiert (Crossref).
Abstract (Originalsprache)
Objective: Triple-negative breast cancer (TNBC) remains a major therapeutic challenge with limited treatment options and poor prognosis. This study aimed to investigate the synergistic anticancer effects of doxorubicin (DOX)... | Find, read and cite all the research you need on Tech Science Press
Zitieren
APA
Hong, C., & Lyu, S. (2025). VCA Augments Doxorubicin Efficacy in Triple-Negative Breast Cancer: Evidence for Multi-Pathway Synergism. BIOCELL, 49(12), 2377-2397. https://doi.org/10.32604/biocell.2025.072360
Vancouver
Hong C, Lyu S. VCA Augments Doxorubicin Efficacy in Triple-Negative Breast Cancer: Evidence for Multi-Pathway Synergism. BIOCELL. 2025;49(12):2377-2397. doi:10.32604/biocell.2025.072360
BibTeX
@article{Hong2025,
author = {Hong, Chang-Eui and Lyu, Su-Yun},
title = {VCA Augments Doxorubicin Efficacy in Triple-Negative Breast Cancer: Evidence for Multi-Pathway Synergism},
journal = {BIOCELL},
year = {2025},
volume = {49},
number = {12},
pages = {2377--2397},
doi = {10.32604/biocell.2025.072360}
}
EUVIMED